Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Oct 1;12(5):759-762.
doi: 10.21037/hbsn-23-342. Epub 2023 Sep 4.

Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved

Masato Yoneda  1 , Takashi Kobayashi  1 , Naohiro Wada  1 , Tomohiro Otani  1 , Asako Nogami  1 , Michihiro Iwaki  1 , Atsushi Nakajima  1
Affiliations
Editorial

Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved

Masato Yoneda et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Nonalcoholic fatty liver disease (NAFLD); nonalcoholic steatohepatitis (NASH); obesity; selective non-acid farnesoid X receptor agonists (selective non-acid FXR agonists); tropifexor.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-342/coif). The authors have no conflicts of interest to declare.

Comment on

  • Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial.
    Sanyal AJ, Lopez P, Lawitz EJ, Lucas KJ, Loeffler J, Kim W, Goh GBB, Huang JF, Serra C, Andreone P, Chen YC, Hsia SH, Ratziu V, Aizenberg D, Tobita H, Sheikh AM, Vierling JM, Kim YJ, Hyogo H, Tai D, Goodman Z, Schaefer F, Carbarns IRI, Lamle S, Martic M, Naoumov NV, Brass CA. Sanyal AJ, et al. Nat Med. 2023 Feb;29(2):392-400. doi: 10.1038/s41591-022-02200-8. Epub 2023 Feb 16. Nat Med. 2023. PMID: 36797481 Free PMC article. Clinical Trial.

References

    1. Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023;77:1335-47. 10.1097/HEP.0000000000000004 - DOI - PMC - PubMed
    1. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023;77:1797-835. 10.1097/HEP.0000000000000323 - DOI - PMC - PubMed
    1. Simon TG, Roelstraete B, Khalili H, et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 2021;70:1375-82. 10.1136/gutjnl-2020-322786 - DOI - PMC - PubMed
    1. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) ; European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-402. 10.1016/j.jhep.2015.11.004 - DOI - PubMed
    1. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017;67:829-46. 10.1016/j.jhep.2017.05.016 - DOI - PubMed